XML 23 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Gilead Stock Purchase Agreement
Common Stock
Private Placement
Common Stock
Additional Paid-in Capital
Gilead Stock Purchase Agreement
Additional Paid-in Capital
Private Placement
Additional Paid-in Capital
Accumulated Deficit
Gilead Stock Purchase Agreement
Private Placement
Total
Beginning balance at Dec. 31, 2022     $ 3     $ 354,752 $ (249,108)     $ 105,647
Beginning balance (in shares) at Dec. 31, 2022     27,425,447              
Stockholders' Deficit                    
Issuance of common stock under employee stock purchase plan           194       194
Issuance of common stock under employee stock purchase plan (in shares)     140,192              
Vesting of restricted common stock (in shares)     39,250              
Exercise of stock options           8       8
Exercise of stock options (in shares)     2,757              
Stock-based compensation expense           7,382       7,382
Net Income (Loss)             (76,404)     (76,404)
Ending balance at Dec. 31, 2023     $ 3     362,336 (325,512)     36,827
Ending balance (in shares) at Dec. 31, 2023     27,607,646              
Stockholders' Deficit                    
Issuance of common stock and prefunded warrants, net of issuance costs $ 1     $ 15,771 $ 9,908     $ 15,772 $ 9,908  
Issuance of common stock and prefunded warrants, net of issuance costs (in shares) 9,105,451 1,953,125                
Issuance of common stock in connection with at-the-market offerings, net of issuance costs     $ 1     6,824       6,825
Issuance of common stock in connection with at-the-market offerings, net of issuance costs (in shares)     7,000,000              
Issuance of common stock under employee stock purchase plan           68       68
Issuance of common stock under employee stock purchase plan (in shares)     76,168              
Vesting of restricted common stock (in shares)     5,617              
Exercise of stock options           5       $ 5
Exercise of stock options (in shares)     8,766             8,766
Stock-based compensation expense           6,434       $ 6,434
Net Income (Loss)             (58,241)     (58,241)
Ending balance at Dec. 31, 2024     $ 5     $ 401,346 $ (383,753)     $ 17,598
Ending balance (in shares) at Dec. 31, 2024     45,756,773